Q2 2026 saw 48% revenue growth year-over-year, driven by strong performance across all therapeutic areas and geographies, with key products like MOUNJARO and ZEPBOUND leading. Full-year guidance was raised, major regulatory and pipeline milestones were achieved, and access to obesity medicines expa…
Q2 2026 saw 48% revenue growth year-over-year, driven by strong performance across all therapeutic areas and geographies, with key products like MOUNJARO and ZEPBOUND leading. Full-year guidance was raised, major regulatory and pipeline milestones were achieved, and access to obesity medicines expanded significantly.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
